Curran Terrie has filed 19 insider transactions across 2 companies since January 2023.
Most recent transaction: a grant/award of 20568 shares of Arcutis Biotherapeutics, Inc. ($ARQT) on June 12, 2025.
Activity breakdown: 1 open-market purchase and 6 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 12, 2025 | Arcutis Biotherapeutics, Inc. | $ARQT | Curran Terrie | Director | A | Stock Option (right to buy) | 20568 | $0.00 | 20,568.0000 | 120,957,633 | 9999.99% | 0.02% |
| June 12, 2025 | Arcutis Biotherapeutics, Inc. | $ARQT | Curran Terrie | Director | A | Common Stock | 7609 | $0.00 | 17,748.0000 | 120,957,633 | 75.05% | 0.01% |
| Feb. 27, 2025 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Stock Option (Right to Buy) | 342500 | $0.00 | 342,500.0000 | 63,176,210 | 9999.99% | 0.54% |
| Jan. 21, 2025 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | S | Common Stock | 19109 | $6.59 | 364,305.1600 | 63,176,210 | 4.98% | 0.03% |
| Nov. 11, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Curran Terrie | Director | S | Common Stock | 8687 | $10.85 | 10,139.0000 | 124,302,317 | 46.14% | 0.01% |
| July 15, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | S | Common Stock | 33848 | $11.72 | 381,574.1600 | 51,289,092 | 8.15% | 0.07% |
| June 14, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Curran Terrie | Director | A | Stock Option (right to buy) | 27052 | $0.00 | 27,052.0000 | 69,305,487 | 9999.99% | 0.04% |
| June 14, 2024 | Arcutis Biotherapeutics, Inc. | $ARQT | Curran Terrie | Director | A | Common Stock | 10139 | $0.00 | 18,826.0000 | 69,305,487 | 116.71% | 0.01% |
| March 22, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | S | Common Stock | 16851 | $9.11 | 414,624.1600 | 51,289,092 | 3.91% | 0.03% |
| Jan. 18, 2024 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Stock Option (Right to Buy) | 475000 | $0.00 | 475,000.0000 | 51,289,092 | 9999.99% | 0.93% |
| Nov. 1, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Common Stock | 37500 | $0.00 | 430,750.6100 | 0 | 9.54% | 0.00% |
| July 14, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Common Stock | 200000 | $0.00 | 393,250.6100 | 0 | 103.49% | 0.00% |
| July 14, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | D | Stock Option | 175000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| July 14, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | D | Stock Option | 225000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| April 6, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | P | Common Stock | 12919 | $7.82 | 190,525.9000 | 0 | 7.27% | 0.00% |
| March 1, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | S | Common Stock | 1436 | $8.54 | 177,606.9000 | 0 | 0.80% | 0.00% |
| Jan. 19, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Common Stock | 97500 | $0.00 | 184,863.9000 | 0 | 111.60% | 0.00% |
| Jan. 20, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | S | Common Stock | 5821 | $8.20 | 179,042.9000 | 0 | 3.15% | 0.00% |
| Jan. 19, 2023 | Phathom Pharmaceuticals, Inc. | $PHAT | Curran Terrie | President and Chief Executive | A | Stock Option (Right to Buy) | 162500 | $0.00 | 162,500.0000 | 0 | 9999.99% | 0.00% |